Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

All Myocarditis, Pericarditis Cases With COVID-19 Vaccines Now Must Be Reported To VAERS

Executive Summary

The change to three vaccine emergency use authorizations was made quietly, most recently for the Novavax vaccine.

You may also be interested in...



FDA Stroke Risk Study Suggests No Need To Change COVID-19 Vaccine Administration Strategy

But new study finds increased risk of non-hemorrhagic stroke in those receiving high-dose adjuvanted flu vaccines, and another study detects new signal for seizures/convulsions among younger children who received COVID vaccine. Authors say findings warrant more investigations.

Pharma Could Lose Some Commercial Info Protections As Part of FDA’s Misinformation Campaign

Commissioner says agency’s speech restrictions to protect confidential commercial information ‘have gone too far,’ and may need to be modified to tackle spread of misinformation. Experts also said US FDA needs to do a better job conveying the uncertainty inherent in its work.

FDA Real-Time Surveillance Not Practical For All Drugs, CDER’s Safety Surveillance Chief Says

Gerald Dal Pan indicated in an interview that the agency's safety systems as now constituted are generating the data needed and that so-called real-time surveillance, which is in place for COVID-19 vaccines and therapeutics, is not practical for all approved products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel